Bartlett JM - Search Results

1

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI. Bartlett JM, et al. J Clin Oncol. 2015 May 20;33(15):1680-7. doi: 10.1200/JCO.2013.54.7869. Epub 2015 Apr 20. J Clin Oncol. 2015. PMID: 25897160

2

HER2 and COX2 expression in human prostate cancer.

Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. Edwards J, et al. Among authors: bartlett jm. Eur J Cancer. 2004 Jan;40(1):50-5. doi: 10.1016/j.ejca.2003.08.010. Eur J Cancer. 2004. PMID: 14687789

3

Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer.

Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. Bartlett JM, et al. J Pathol. 2005 Mar;205(4):522-9. doi: 10.1002/path.1735. J Pathol. 2005. PMID: 15685688

4

The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.

Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. Edwards J, et al. Among authors: bartlett jm. Clin Cancer Res. 2006 Jan 1;12(1):123-30. doi: 10.1158/1078-0432.CCR-05-1445. Clin Cancer Res. 2006. PMID: 16397033 Free article.

5

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P. Bartlett JM, et al. J Clin Oncol. 2007 Oct 1;25(28):4423-30. doi: 10.1200/JCO.2007.11.0973. J Clin Oncol. 2007. PMID: 17906205

6

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Bartlett JM, et al. J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2. J Clin Oncol. 2008. PMID: 18768436 Clinical Trial.

7

Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?

Bartlett JM, Campbell FM, Mallon EA. Bartlett JM, et al. Am J Clin Pathol. 2008 Dec;130(6):920-6. doi: 10.1309/AJCPSDG53BEANCYE. Am J Clin Pathol. 2008. PMID: 19019769

8

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.

Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Connolly Y, Campbell F, O'Grady A, Barnett S, Miller K. Bartlett JM, et al. Am J Clin Pathol. 2009 Jan;131(1):106-11. doi: 10.1309/AJCPLN78ZQXEMNMA. Am J Clin Pathol. 2009. PMID: 19095573

9

Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.

Faratian D, Munro A, Twelves C, Bartlett JM. Faratian D, et al. Among authors: bartlett jm. Histopathology. 2009 Jan;54(2):254-7. doi: 10.1111/j.1365-2559.2008.03191.x. Histopathology. 2009. PMID: 19207951

10

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients.

McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, Cooke TG. McGlynn LM, et al. Among authors: bartlett jm. Clin Cancer Res. 2009 Feb 15;15(4):1487-95. doi: 10.1158/1078-0432.CCR-07-4967. Clin Cancer Res. 2009. PMID: 19228750 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

334 results

Search Page

Filters